| Literature DB >> 31771160 |
Tomasz Olszak1, Katarzyna Danis-Wlodarczyk1,2, Michal Arabski3, Grzegorz Gula1, Barbara Maciejewska1, Slawomir Wasik4, Cédric Lood2,5, Gerard Higgins6,7, Brian J Harvey7, Rob Lavigne2, Zuzanna Drulis-Kawa1.
Abstract
The emergence of phage-resistant mutants is a key aspect of lytic phages-bacteria interaction and the main driver for the co-evolution between both organisms. Here, we analyze the impact of PA5oct jumbo phage treatment on planktonic/cell line associated and sessile P. aeruginosa population. Besides its broad-spectrum activity and efficient bacteria reduction in both airway surface liquid (ASL) model, and biofilm matrix degradation, PA5oct appears to persist in most of phage-resistant clones. Indeed, a high percentage of resistance (20/30 clones) to PA5oct is accompanied by the presence of phage DNA within bacterial culture. Moreover, the maintenance of this phage in the bacterial population correlates with reduced P. aeruginosa virulence, coupled with a sensitization to innate immune mechanisms, and a significantly reduced growth rate. We observed rather unusual consequences of PA5oct infection causing an increased inflammatory response of monocytes to P. aeruginosa. This phenomenon, combined with the loss or modification of the phage receptor, makes most of the phage-resistant clones significantly less pathogenic in in vivo model. These findings provide new insights into the general knowledge of giant phages biology and the impact of their application in phage therapy.Entities:
Keywords: Airway Surface Liquid Infection model; Pseudomonas aeruginosa; biofilm; giant bacteriophage; phage-resistant mutants
Mesh:
Year: 2019 PMID: 31771160 PMCID: PMC6950013 DOI: 10.3390/v11121089
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Phage receptor identification on P. aeruginosa PAO1 mutants.
| PAO1 Isolates | Phenotype | PA5oct Activity |
|---|---|---|
| ATCC 15692 (PAO1) | Wild type | + |
| Δrmd (A−, B+) * | Deficiency in D-rhamnose biosynthesis; lack of A-band LPS | + |
| ΔwaaL (A−, B−) * | Lack of WaaL ligating O-polymer to core-lipid A; LPS is devoid of A-band and B-band, semirough (SR-LPS, or core-plus-one O-antigen) | −/+ |
| ΔwbpL (A−, B−) * | Lack of glucosyltransferase WbpL essential for initiation of both A-band and B-band synthesis | − |
| ΔfliC ΔalgC ΔpilA ** | Lack of flagella; lack of AlgC required for A-band, core oligosaccharide, and alginate biosynthesis; lack of Type IV pili | − |
| ΔfliC ΔpilA ** | Lack of flagella; lack of Type IV pili | − |
| ΔfliC WTpilA ** | Lack of flagella | −/+ |
(+)—clear plaque; (−)—lack of lytic activity; (+/−)—opaque plaque; * Laboratory of Foodborne Zoonoses, Guelph, Canada, Andrew M. Kropinski; ** Technical University Hamburg, Germany, Max Schöbert.
Figure 1Phage PA5oct treatment of . Colony count of bacteria collected from apical wash. The gray bars represent bacteria titers after 1.5 h of incubation with PA5oct phage. The black bars represent controls without phage treatment. The error bars indicate the standard deviation. The results are presented as the means ± SD. Statistical analysis was made using the ANOVA test (denoted p-values < 0.05). (*) the instance with p-values < 0.05.
Figure 2Real time measurement of biofilm permeability, after 4 h of phage treatment. (A) Membrane coverage analysis by crystal violet (CV) staining and ImageJ imaging software. Native membrane was used as a control. (B) Laser interferometry analysis of trypticase-soy broth (TSB) medium diffusion through PAO1 biofilm treated with PA5oct phage. Untreated biofilm was used as a control. Error bars denote SD. The results displayed are the mean of three independent experiments. Statistical analysis was made by the ANOVA test to compare data of treated biofilm versus control native biofilm at 40 min time point. The examples of interferograms (40 min) for PAO1 biofilm treated with active and inactivated PA5oct phages as well as control (from the top of a right-hand panel).
Figure 3The anti-biofilm effect of PA5oct phage treatment (4 h) on 24, 48 and 72 h PAO1 biofilm formed on Nephrophane membrane. The biomass evaluation by CV staining (A); the level of pyocyanin in growth medium (B); the fluorescence of pyoverdin in growth medium (C). Untreated biofilm was used as control. The results are presented as the means ± SD. Statistical analysis was made by the ANOVA test (denoted p-values < 0.05). (*) the instance with p-values < 0.05.
Phage typing of PA5oct clones obtained during biofilm treatment.
| Bacterial Clones | Susceptibility to Phage Infection | Number of Isolates | |||||||
|---|---|---|---|---|---|---|---|---|---|
| LPS/Pili | LPS-Dependent | Pili-Dependent | |||||||
| PA5oct | LBL3 | KT28 | KTN6 | LUZ7 | KTN4 | phiKZ | LUZ19 | ||
| Control planktonic PAO1 | + | + | + | + | + | + | + | + | 1 |
| Control biofilm PAO1 | + | + | + | + | + | + | + | + | 30 |
| PA5oct sensitive | + | + | + | + | + | + | + | + | 10 |
| PA5oct resistant type 1 | − | − | + | + | + | − | + | + | 1 |
| PA5oct resistant type 2 | − | − | + | + | + | − | − | + | 2 |
| PA5oct resistant type 3 | − | + | − | − | + | − | + | + | 2 |
| PA5oct resistant type 4 | − | + | − | − | + | + | + | + | 5 |
| PA5oct resistant type 5 | − | − | − | − | + | + | + | + | 10 |
(+) sensitive to phage infection; (−) resistant to phage infection.
The virulence features of P. aeruginosa clones after PA5oct treatment.
| Bacterial Clones | Name | LPS Pattern | Growth Rate [OD590/24 h] | Larvae Survival Rate [%] (18/24/48/72 h) | Twitching Motility [mm] | Phage DNA Presence (PCR) | ΔCT PAO1/ΔCT PA5oct Ratio |
|---|---|---|---|---|---|---|---|
| control planktonic | PAO1 | S | >1.5 | 10/0/0/0 | 24.2 ± 1.3 | − | − |
| control biofilm | K72A | S | >1.5 | 30/0/0/0 | 23 ± 2.0 | − | − |
| control biofilm | K72B | S | >1.5 | 30/0/0/0 | 22.9 ± 1.9 | − | − |
| control biofilm | K72C | S | >1.5 | 10/0/0/0 | 22.8 ± 2.3 | − | − |
| control biofilm | K72D | S | >1.5 | 5/0/0/0 | 22.7 ±1.5 | − | − |
| control biofilm | K72E | S | >1.5 | 15/0/0/0 | 23.5 ± 1.3 | − | − |
| control biofilm | K72F | S | >1.5 | 0/0/0/0 | 23.8 ± 1.2 | − | − |
| control biofilm | K72G | S | >1.5 | 5/0/0/0 | 23.7 ± 1.6 | − | − |
| control biofilm | K72H | S | >1.5 | 35/0/0/0 | 23.3 ± 2.1 | − | − |
| control biofilm | K72I | S | >1.5 | 15/0/0/0 | 23.8 ± 1.1 | − | − |
| control biofilm | K72J | S | >1.5 | 25/0/0/0 | 23.2 ± 1.5 | − | − |
| PA5oct sensitive | 24F | S | <1.0 | 15/0/0/0 | 18.2 ± 0.9 * | − | − |
| PA5oct sensitive | 48B | S | >1.5 | 20/10/0/0 | 18.5 ± 1.0 * | − | − |
| PA5oct sensitive | 48C | S | >1.5 | 80/35/0/0 ** | 19.3 ± 1.3 * | − | − |
| PA5oct sensitive | 48F | S | >1.5 | 30/0/0/0 | 15.7 ± 0.8 * | − | − |
| PA5oct sensitive | 48G | S | >1.5 | 80/40/15/0 ** | 19 ± 0.8 * | − | − |
| PA5oct sensitive | 72B | S | >1.5 | 30/25/10/0 ** | 18.4 ± 1.3 * | − | − |
| PA5oct sensitive | 72C | S | <1.0 | 80/55/10/0 ** | 15.5 ± 1.3 * | + | 1.7 |
| PA5oct sensitive | 72E | S | >1.5 | 55/25/0/0 ** | 14.6 ± 0.7 * | − | − |
| PA5oct sensitive | 72F | S | >1.5 | 20/0/0/0 | 18.3 ± 0.8 * | − | − |
| PA5oct sensitive | 72G | S | >1.5 | 30/15/0/0 | 18.5 ± 1.1 * | − | − |
| PA5oct resistant type 1 | 48H | S | <1.0 | 100/95/75/60 ** | 5.5 ± 1.3 * | + | 0.8 |
| PA5oct resistant type 2 | 24C | S | <1.0 | 75/60/55/35 ** | 15.4 ± 1.0 * | + | 0.8 |
| PA5oct resistant type 2 | 48A | S | <1.0 | 70/65/30/0 ** | 17.5 ± 1.8 * | + | 1.0 |
| PA5oct resistant type 3 | 48E | S | <1.0 | 100/45/0/0 ** | 19.1 ± 1.3 * | + | 0.9 |
| PA5oct resistant type 3 | 72H | S | <1.0 | 95/55/10/0 ** | 13.6 ± 1.6 * | + | 0.8 |
| PA5oct resistant type 4 | 24A | S | <1.0 | 50/15/15/15 ** | 16.7 ± 2.0 * | + | 2.0 |
| PA5oct resistant type 4 | 24D | S | >1.5 | 75/60/40/20 ** | 11 ± 2.3 * | + | 1.0 |
| PA5oct resistant type 4 | 48I | S | <1.0 | 85/60/20/0 ** | 13.2 ± 0.6 * | + | 0.9 |
| PA5oct resistant type 4 | 48J | S | <1.0 | 80/60/15/15 ** | 15.4 ± 1.2 * | + | 1.1 |
| PA5oct resistant type 4 | 72I | S | <1.0 | 55/50/5/0 ** | 14 ± 1.1 * | + | 1.2 |
| PA5oct resistant type 5 | 24B | S | <1.0 | 85/80/40/40 ** | 16.5 ± 1.6 * | + | 1.0 |
| PA5oct resistant type 5 | 24E | S | <1.0 | 75/70/55/30 ** | 15.4 ± 1.6 * | + | 1.0 |
| PA5oct resistant type 5 | 24G | S | <1.0 | 75/70/65/35 ** | 12.5 ± 2.1 * | + | 1.0 |
| PA5oct resistant type 5 | 24H | S | <1.0 | 95/75/45/35 ** | 12.2 ± 1.3 * | + | 0.8 |
| PA5oct resistant type 5 | 24I | S | >1.5 | 100/80/55/35 ** | 13.3 ± 0.8 * | + | 1.0 |
| PA5oct resistant type 5 | 24J | S | >1.5 | 85/70/50/30 ** | 14.5 ± 1.7 * | + | 1.3 |
| PA5oct resistant type 5 | 48D | S | <1.0 | 85/45/15/0 ** | 14.4 ± 0.7 * | + | 0.8 |
| PA5oct resistant type 5 | 72A | S | <1.0 | 95/70/0/0 ** | 12.5 ± 1.7 * | + | 1.0 |
| PA5oct resistant type 5 | 72D | S | >1.5 | 100/75/15/0 ** | 13.2 ± 0.9 * | + | 0.9 |
| PA5oct resistant type 5 | 72J | S | <1.0 | 95/80/10/0 ** | 22.8 ± 1.3 * | + | 1.0 |
(S)—smooth LPS type; (*) significantly lower TM zone compared to control clones (One way ANNOVA, P < 0.05); (**) significantly higher G. mellonella larvae survival rate compared to infected by control clones (Log-rank (Mantel-Cox), P < 0.05; ΔCT PAO1/ΔCT PA5oct ratio: <0.8—an increase in the number of phage DNA copies in relation to bacteria DNA; 0.8–1.3—equilibrium of phage and bacterial DNA copies; >1.3—the predominance of bacterial DNA over phage DNA copies.
Figure 4Phenotypic patterns in PAO1 clones treated with PA5oct. Growth curves (A,C,E,G) of selected bacterial clones combined with a survival of infected G. mellonella (B,D,F,H) for PA5oct-sensitive and PA5oct-resistant clones. Fast-growing with a high virulence (control and 72F; (A)/(B)); slow-growing with a high virulence (24F; (C)/(D)); fast-growing with a low virulence (24I; (E)/(F)), and slow-growing with a low virulence (48H; (G)/(H)). Data for all clones are presented in Supplementary Figure S2.